Reversibility of Acute Demyelinating Lesions in relapsingremitting



Similar documents
ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

MS ECHO: Update on MS treatment. Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology

OHTAC Recommendation

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

AUBMC Multiple Sclerosis Center

Progress in MS: Current and Emerging Therapies

What is Multiple Sclerosis? Gener al information

Using the MS Clinical Course Descriptions in Clinical Practice

PROPOSED REVISIONS TO THE CRITERIA. multiple sclerosis (RRMS)] Chapter 6 6 It is recognised that use is in only exceptional circumstances in RRMS.

A Definition of Multiple Sclerosis

Chapter 10. Summary & Future perspectives

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

Natalizumab (Tysabri)

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

Accuracy in Space and Time: Diagnosing Multiple Sclerosis Genzyme Corporation, a Sanofi company.

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December Reference : NHSCB/D4/c/1

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

How To Use A Drug In Multiple Sclerosis

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

Multiple Sclerosis: What You Need To Know. For Professionals

Update: MRI in Multiple sclerosis

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

AUBAGIO (teriflunomide) oral tablet

New Treatment Options for MS Patients: Understanding risks versus benefits

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

Multiple Sclerosis. Matt Hulvey BL A - 615

Case Report. Central Neurocytoma. Fotis Souslian, MD; Dino Terzic, MD; Ramachandra Tummala, MD. Department of Neurosurgery, University of Minnesota

Intrathecal Baclofen for CNS Spasticity

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS)

F r e q u e n t l y A s k e d Q u e s t i o n s

Supplementary appendix

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

FastTest. You ve read the book now test yourself

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

National MS Society Information Sourcebook

fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK

MS Treatments Aubagio TM

CBT IN THE CITY. adjusted to the news of being with MS? April Experts at your fingertips call now. Check out our new services in you local area

Management of spinal cord compression

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families

Acute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD

An introduction to modern MS treatments

Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

Multiple Sclerosis Jeffrey M. Gelfand, MD

MRI in Differential Diagnosis

TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Intravenous Methyl Prednisolone in Multiple Sclerosis

Media Release. Basel, 8 October 2015

MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author

Steroids. What are steroids?

MS Treatments Gilenya

2.1 Who first described NMO?

Headache: Differential diagnosis and Evaluation. Raymond Rios PGY-1 Pediatrics

Clinical Study Synopsis

Immunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020

March 30, I. IVIg IS AN ACCEPTED THERAPY FOR RRMS, AND IS PRESCRIBED ALONG WITH A DISEASE-MODIFYING AGENT SUCH AS COPAXONE

Guidelines for Medical Necessity Determination for Speech and Language Therapy

Held, Heigenhauser, Shang, Kappos, Polman: Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials

Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.

Clinical features. Chapter 2. Clinical manifestations. Course

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Stuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation

Clinical Trials of Disease Modifying Treatments

The Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment

Clinically isolated syndrome (CIS)

Interferon-β-1a in relapsing-remitting multiple sclerosis: evect on hypointense lesion volume on T1 weighted images

Transcription:

Reversibility of Acute Demyelinating Lesions in relapsingremitting Multiple Sclerosis Omar A. Khan ( Division of Neuroimmunology, Department of Neurology, Neurology and Research Services. Veterans Affairs Medical Center, Baltimore. ) Michael I. Rothman ( Section of Neuroradiology, Department of Diagnostic Radiology, University of Maryland School of Medicine. Baltimore. ) Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) of presumed autoimmune etiology and characterized by a relapsing-remitting course 1. Brain magnetic resonance imaging (MRI) has emerged as the most sensitive investigation to detect demvelitiation in MS 2,3. Furthermore, acute relapses of MS have been associated with breakdown of the blood-brain barrier (BBB) 4 seen as contrast enhancement on brain MR( TI-weighted images 5. Recently, we encountered a case of an acute relapse in a patient with known MS. ireatment with h igh-dose intravenous methylprednisolone (IVMP) resulted in clinical recovery as well as resolution of brain MRI abnormalities. This patient represents a striking case of complete reversibility of acute demyelinating lesions seen on brain MRI scans. Case Report A 30 vear old woman with a history of relapsing-remitting MS for several years presented with acute dysarthria, weakness, difficulty in walking and headache of four hours duration. Prior to the onset of symptoms she had been stable for several months. Her only medication was baclofen Vital signs were within normal limits and general physical examination was also normal. Neurological examination was pertinent for mild dysarthria, right hemiparesis, hyperreflexia (more prominent on the right) with bilateral Babinskis signs and spastic ity mild vibratory loss in both distal lower extremities and impaired coordination on the right. She required assistance to ambulate. She was admitted with the diagnosis of acute relapse of MS. Blood counts and routine chemistries were normal. A brain MRI scan with and without contrast was obtained. A well defined area of increased signal intensity adjacent to the anterior horn of left lateral ventricle on axial T2-weighted image was seen (figure I A)

with a ring like contrast enhancement seen on axial TI -weighted image (figure 1 B).

Treatment with IVMP was instituted at one gram a day for five days followed by a brief taper of oral prednisone. The patient had complete clinical recovery one week after the onset of treatment. A follow up brain MRI scan was obtained two weeks after the first scan. There was significantly diminished signal intensity seen on axial T-2 weighted image (figure 2A)

without any enhancement on axial T-1 weighted image (figure 2B).

The patient was discharged and continues to do well one year later. Discussion This case highlights the MRI changes seen during an acute demyelinating event associated with clinical

worsening as well as alteration of the BBB 6. The role of brain MRI in detecting acute denivel ination is well established 2 Although this patient had Well established MS and had been followed at our clinic for several years, other diagnostic considerations in a patient with no previous medical history, should include cerebral abscess. primary or secondary brain tumor, toxoplasmosis. parasitic cyst. neuroborreliosis. neurosarcoidosis and tuberculosis 7. Thus, careful consideration should be paid to the differential diagnosis of MRl abnormalities seen during an acute neurological event and follow up studies should be obtained if deemed appropriate in order to conlirm the initial diagnosis. Treatment with high dose IVMP is generally considered to be the treatment of choice for an acute relapse of MS 8. The eliect on brain MRI lesions including contrast enhancement is variable though clinical recovery usually ensues 9. Most studies show that NMP suppresses contrast enhancement in acute demvelinating lesions 10 This effect is attributed primarily to decreased permeability of the BBB 12,13. Although. one could argue that such resolution of MRI abnormalities could also represent the natural course of relapsing remitting MS. H owever, radiological resolution of acute MS plaques typically occurs over a period of at least 6 to 8 weeks 14. This case highlights the abnormalities which may be seen on brain MRI during an acute relapse of MS. Furthermore, treatment with high dose IVM P confirmed temporal correlation between clinical improvement and reversal of acute MRI changes including suppression of contrast enhancement. References 1.McAlpine D, Compston ND, Acheson ED. Multiple sclerosis: a reappraisal, 2nd ed. London: Churchill Livingstone, 1972:214. 2.Ormerod IEC, Miller DH, McDonald WI, et al. The role of MRI in the assessment of MS and isolated neurological lesions: a quantitative study. Brain, 1987:110:1579-1616. 3.Miller DH. MRI: Sensitive and safe in diagnosing MS. MRI Decisions, 1988;2: 7-24. 4.McFarland H, Frank JA, Albert PS, et al. Using gadolinium enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol., I 992;32:758-66. 5.Smith ME, Stone LA, Albert PA, et al. Clinical worsening in MS associated with increased frequency and area of gadopenlale dimeglunmine enhancing amagnetic resonance imaging lesions. Ann. Neurol., 1 993:33 :480-89. 6.Gonzalez-Scarano F, Grossman RI, Galetta S, et al. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann. Neurol., 1987;21 :300-6. 7.n\' AG: Diagnostic Neuroradiology. St. Louis, Moshy, 1994. 8,Durelli L, Cocito D, Riceio A, et al. High dose intravenous methylprednisolone versus ACTH in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology, 1986;36:238-43. 9.Milligan NM, Newcombc R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1 Clinical effects. J. ncurol. Neurosurg. Psychiatry, 1987:50:511-16. 10.Burnham JA, Wright RR. Dreisbach J, et al, The effect of high-close steroids on MRI gadolinium enhancement in acute demyclinaling lesions. Neurology. 1991:41:1349-54. 11.Trotter JL, Garvey WE. Prolonged effects of large-dose methyprednisolone infusion in multiple sclerosis. Neurology, 180:30:702-8. 12.Kermode AG, Tofts PS, Thompson Al, ci al. Heterogeneity of blood brain barrier changes in multiple sclerosis: an MRI study with gadolinium-dtpa enhancement. Neurology, 1990:40:229-35. 13.Miller DH, Thompson AJ, Morrisey SP, et al. High-dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic etlect. J. Neurol, Neurosurg. Psychiatry, 1992;55:450-53.

14.Capra R. Gadolinium-pentetic acid MRI in patients with relapsing remitting MS. Arch, Neurol., 1992:49:687-89.